Mesothelioma Linked to Shipbuilding Finally Falling in the UK

mesothelioma linked to shipbuilding

After decades of higher-than-normal rates of mesothelioma near dockyards, cases of mesothelioma linked to shipbuilding appear to be falling in the UK. The UK has one of the highest per capita rates of malignant mesothelioma in the world. A big part of that comes from the shipbuilding industry where asbestos was used extensively. Now, a new report suggests the scourge of mesothelioma linked to shipbuilding is finally beginning to taper off, even though deaths from mesothelioma have not.  Why is Mesothelioma Linked to Shipbuilding? Asbestos is a naturally-occurring mineral that is strong and impervious to heat and corrosion. That made it a good insulator and a choice building material for many decades. Unfortunately, asbestos is also highly toxic.  Before scientists … Continue reading Mesothelioma Linked to Shipbuilding Finally Falling in the UK »

Supplement May Boost the Effectiveness of Mesothelioma Treatment

boost the effectiveness of mesothelioma treatment

A supplement that claims to increase oxygen in the tissues might boost the effectiveness of mesothelioma treatment.  That is the conclusion of researchers at Italy’s National Cancer Institute in Rome.  The group tested the supplement Cellfood (CF) on several types of cancer cells in the lab. They also gave the supplement to mice with implanted human mesothelioma tumors.  CF appeared to boost the effectiveness of mesothelioma treatment with radiation or chemoradiation.  What is Cellfood? Cellfood (Deutrosultazyme) is a nutraceutical produced by NuScience Corporation. A nutraceutical is a nutritional supplement that may function like a drug in some ways. According to NuScience, Cellfood contains colloidal minerals, amino acids, enzymes, and dissolved oxygen. Lab studies show that it has antioxidant effects and … Continue reading Supplement May Boost the Effectiveness of Mesothelioma Treatment »

Mesothelioma Clinical Trials: Study Highlights Challenges for Patients

mesothelioma clinical trials

A new UK study points to some of the potential challenges and benefits for patients involved in mesothelioma clinical trials.  Researchers at three teaching hospitals in England interviewed mesothelioma patients who took part in the Mesothelioma and Radical Surgery (MARS 2) trial.  The trial compared outcomes in people who had a combination of surgery and chemotherapy with those who only had chemotherapy. The findings show that not all aspects of mesothelioma clinical trials are positive for patients.  A Study Within a Study Pleural mesothelioma is a fast-growing cancer that starts on the lining around the lungs. Asbestos exposure is usually the cause. With standard cancer treatments, most mesothelioma patients face a poor prognosis. Mesothelioma often leads to death within a … Continue reading Mesothelioma Clinical Trials: Study Highlights Challenges for Patients »

Biphasic Mesothelioma Survival Possible in Select Patients

biphasic mesothelioma survival

A new report contains some hopeful news about biphasic mesothelioma survival.  Biphasic mesothelioma is the rarest subtype of a rare cancer. It is also the subtype that is hardest to treat.  Biphasic mesothelioma survival is typically shorter than other subtypes. But Italian researchers say, with the right combination of mesothelioma treatments, patients with this subtype can achieve long-term survival. Subtypes and their Impact on Biphasic Mesothelioma Survival All pleural mesothelioma tumors grow on the membrane that surrounds the lungs. When this membrane is healthy, it is flexible and expands naturally with each breath.  When a mesothelioma tumor grows on this membrane, it can restrict the lungs and make it hard to breathe. As tumors grow, mesothelioma can spread to other … Continue reading Biphasic Mesothelioma Survival Possible in Select Patients »

Machine Learning Tool May Predict Mesothelioma Survival Better Than Pathologists

machine learning tool

The developers of a machine learning tool called MesoNet say the program can predict mesothelioma survival better than a pathologist. MesoNet is a deep convolutional neural network. It analyzes digitized images of mesothelioma cells to predict overall survival. In a new article in Nature Medicine, its creators compared the machine learning tool with pathologist-read slides. Then they validated MesoNet with two different sets of mesothelioma patients.  The result may offer a new, more accurate approach to mesothelioma treatment planning.  What is a Machine Learning Tool? A machine learning tool is a computer program that gets “smarter” the more it runs. A deep convolutional neural network is a type of machine learning tool that analyzes images. The more images it analyzes, … Continue reading Machine Learning Tool May Predict Mesothelioma Survival Better Than Pathologists »

Mesothelioma Among Construction Workers in Southern Italy

mesothelioma among construction workers

New research in Southern Italy highlights the global problem of mesothelioma among construction workers.  The research comes from occupational medicine experts at the University of Bari.  Scientists studied 178 cases of mesothelioma among construction workers in the Apulia region of Italy. The data shows that heavy asbestos exposure raised the odds of contracting mesothelioma by more than two-and-a-half times.  Asbestos and the Risk for Mesothelioma Asbestos is the primary cause of mesothelioma, in Italy and around the world. But for decades, almost no one knew that.  Tens of thousands of people worked with asbestos before scientists recognized the risk for mesothelioma among construction workers.  Asbestos was in dozens of construction products including cement, wall board, insulation, floor and ceiling tiles … Continue reading Mesothelioma Among Construction Workers in Southern Italy »

Pembrolizumab for Mesothelioma Dealt Setback by New Trial Results

pembrolizumab for mesothelioma

There has been a setback for researchers focused on the promise of pembrolizumab for mesothelioma. New research suggests that pembrolizumab (Keytruda) may not be the miracle mesothelioma drug that some were hoping for.  The Phase III trial results were presented at a the European Society of Medical Oncology conference now underway in Spain. They suggest that pembrolizumab for mesothelioma may be no better than chemotherapy for improving survival. Pembrolizumab for Mesothelioma: How it Works Malignant pleural mesothelioma is a rare but lethal cancer. It is usually associated with on-the-job asbestos exposure. There is no cure. The only drug approved for mesothelioma treatment is Alimta (pemetrexed).   Cancer researchers around the world are working hard to find other mesothelioma treatments. Pembrolizumab for … Continue reading Pembrolizumab for Mesothelioma Dealt Setback by New Trial Results »

Talc Pleurodesis for Mesothelioma May Extend Survival

talc pleurodesis for mesothelioma

A UK study suggests that successful talc pleurodesis for mesothelioma improves survival better than other lung fluid treatments.  Researchers in Oxford’s Chest Diseases Department analyzed the outcomes of two groups of pleural mesothelioma patients. Both groups underwent talc pleurodesis for mesothelioma.  The patients whose lung fluid did not come back after treatment experienced longer survival. Mesothelioma patients who had to be retreated did not live as long.  Pleural Effusion in Mesothelioma The pleura is a membrane that surrounds and encases the lungs. It is supposed to be flexible and allow the lungs to move when a person breathes.  But patients with pleural mesothelioma often develop pleural effusion. Pleural effusion is a build-up of excess fluid in the space between the … Continue reading Talc Pleurodesis for Mesothelioma May Extend Survival »

First-Line Keytruda Treatment May Support Longer Mesothelioma Survival

first-line Keytruda treatment

New data suggests first-line Keytruda treatment helps lung cancer patients more than chemotherapy – even if chemotherapy patients add Keytruda later. The news is likely to have implications for people with pleural mesothelioma, too. German researchers presented the data earlier this week at the World Lung Cancer Conference in Barcelona.  The presentation was based on three years of the KEYNOTE-024 trial. The trial focused on lung cancer. But Keytruda is also an up-and-coming drug for malignant pleural mesothelioma. Pleural mesothelioma is a lung-related cancer similar to non-small cell lung cancer.  Blocking PD-L1 with First-Line Keytruda Treatment Keytruda is the brand name for pembrolizumab. It is an immune checkpoint inhibitor that blocks a protein called PD-L1. To be eligible for first-line … Continue reading First-Line Keytruda Treatment May Support Longer Mesothelioma Survival »

Lung Cancer Blood Test: Can it Find Early Mesothelioma?

lung cancer blood test for mesothelioma

Mesothelioma patients and their doctors may have reason to be optimistic about a new lung cancer blood test. A random trial of more than 12,000 high-risk people in Scotland shows the EarlyCDT test combined with CT imaging can detect cancer early. Earlier diagnosis is likely to lead to longer survival of lung cancers like pleural mesothelioma. Researchers presented their findings on the new lung cancer blood test at a global conference this week in Spain. Largest Lung Cancer Trial As in the US, lung cancer is the biggest cancer killer in Scotland. Pleural mesothelioma is a form of lung cancer. Although it is rare, mesothelioma is more common in the UK than in other parts of the world. This is … Continue reading Lung Cancer Blood Test: Can it Find Early Mesothelioma? »

Get your free copy of
“Surviving Mesothelioma” Today!